RenovoRx, Inc. Common Stock

Day range

$1.27 – $1.34

Open

$1.30

Prev close

$1.29

Volume

129.73K

Market cap

$58.22M

Shares out

45.13M

P/E

—

P/S

29.46

P/B

6.48

P/FCF

—

ROE

-136.8%

ROA

-107.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Listing compliance regainedAug 20, 2026

  On August 20, 2026, the Company received written confirmation from Nasdaq notifying the Company that for the ten consecutive business days from August 6, 2026 through August 19, 2026, the closing bid price of the Common Stock had been $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement and Nasdaq considers the matter closed.

• Investor presentationAug 4, 2026

  RenovoRx, Inc. (the "Company") issued a press release announcing the Company's expected participation in a JonesTrading key opinion leader webinar relating to pancreatic cancer and the Company's technology platform to be held on August 13, 2026.

• Listing deficiency noticeJul 2, 2026

  On July 1, 2026, the Company received a notification letter from Nasdaq informing the Company that, while the Company has not yet regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until December 28, 2026 (the "Second Compliance Period"), to regain compliance.

• Annual meeting resultsJun 30, 2026

  At the Annual Meeting, the Company's stockholders elected each of Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP as a director for a one-year term that expires at the Company's 2027 annual meeting of stockholders or until a successor is duly elected and qualified.

• Executive officer appointmentMar 27, 2026

  On March 24, 2026, the board of directors (the "Board") of RenovoRx, Inc., a Delaware corporation (the "Company"), formally appointed Ramtin Agah, M.D., Chief Medical Officer and Chairman of the Board of the Company, to the newly created position of Executive Chairman, effective February 27, 2026.

Days to cover

1.6

Short interest

946.98K

Avg volume

597.35K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
  positiveGlobeNewswire Inc.· Aug 25, 2026
• RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
  positiveGlobeNewswire Inc.· Apr 1, 2026
• University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
  GlobeNewswire Inc.· Jun 26, 2024
• RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
  GlobeNewswire Inc.· Jun 10, 2024
• Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
  Benzinga· Jan 2, 2024